Press coverage about Sabra Health Care REIT (NASDAQ:SBRA) has trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sabra Health Care REIT earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave press coverage about the real estate investment trust an impact score of 44.9588611904431 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:
- Jefferies Downgrades Sabra Healthcare REIT Inc. (SBRA) to Hold, Says Execution Risk Around the Genesis Portfolio Sale Creates an Overhang (streetinsider.com)
- $0.67 EPS Expected for Sabra Health Care REIT Inc (SBRA) This Quarter (americanbankingnews.com)
- Your Today’s Wake-Up Call: Sabra Health Care REIT, Inc. (SBRA), Patterson Companies, Inc. (PDCO) – Market Movers (financialqz.com)
- Sabra Health Care REIT, Inc. (SBRA) : Consensus Analysts Rating is Good For Investors? – Wall Street Morning (wallstreetmorning.com)
- Sabra Health Care REIT (SBRA) Receives “Hold” Rating from Jefferies Group (americanbankingnews.com)
Shares of Sabra Health Care REIT (SBRA) traded up $0.08 during trading on Friday, hitting $18.71. 1,365,082 shares of the company were exchanged, compared to its average volume of 1,750,000. The firm has a market cap of $3,350.00, a PE ratio of 23.99, a P/E/G ratio of 2.42 and a beta of 0.92. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 0.89. Sabra Health Care REIT has a 1-year low of $18.48 and a 1-year high of $29.10.
A number of equities analysts have recently commented on the stock. Raymond James Financial reaffirmed a “hold” rating on shares of Sabra Health Care REIT in a report on Wednesday, December 13th. Jefferies Group reaffirmed a “buy” rating and set a $24.00 price objective (down from $25.00) on shares of Sabra Health Care REIT in a report on Wednesday, September 27th. Cantor Fitzgerald reiterated a “buy” rating and set a $30.00 target price on shares of Sabra Health Care REIT in a research report on Thursday, September 28th. Zacks Investment Research cut shares of Sabra Health Care REIT from a “buy” rating to a “hold” rating in a research report on Friday, September 22nd. Finally, Capital One Financial assumed coverage on shares of Sabra Health Care REIT in a research report on Monday, September 25th. They set an “equal weight” rating and a $24.00 target price for the company. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $24.40.
In other Sabra Health Care REIT news, Director Milton J. Walters sold 4,615 shares of the firm’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $19.18, for a total value of $88,515.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.60% of the company’s stock.
About Sabra Health Care REIT
Sabra Health Care REIT, Inc is a real estate investment trust. The Company, through its subsidiaries, owns and invests in real estate serving the healthcare industry. The Company’s segment includes investments in healthcare-related real estate properties. The Company’s primary business consists of acquiring, financing and owning real estate property to be leased to third-party tenants in the healthcare sector.
Receive News & Ratings for Sabra Health Care REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sabra Health Care REIT and related companies with MarketBeat.com's FREE daily email newsletter.